Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone fluid retention in insulin-treated T2DM with neuropathy
NCT00422955Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rosiglitazone in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Nov 2003; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00422955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422955.